{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:35:17Z","timestamp":1791214517241,"version":"4.1.0"},"reference-count":36,"publisher":"The Endocrine Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,6,1]]},"DOI":"10.1210\/jc.2007-2564","type":"journal-article","created":{"date-parts":[[2008,3,12]],"date-time":"2008-03-12T03:33:44Z","timestamp":1205292824000},"page":"2057-2062","source":"Crossref","is-referenced-by-count":120,"title":["Treatment of Advanced Adrenocortical Carcinoma with Erlotinib plus Gemcitabine"],"prefix":"10.1210","volume":"93","author":[{"given":"Marcus","family":"Quinkler","sequence":"first","affiliation":[{"name":"Department of Clinical Endocrinology (M.Q., C.S.), Charite\u0301 Campus Mitte, Charite\u0301 University Medicine Berlin, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Hahner","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I (S.H., S.W., S.J., B.A., M.F.), University of Wuerzburg, 97080 Wuerzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Wortmann","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I (S.H., S.W., S.J., B.A., M.F.), University of Wuerzburg, 97080 Wuerzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Johanssen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I (S.H., S.W., S.J., B.A., M.F.), University of Wuerzburg, 97080 Wuerzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Adam","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Diabetes Unit, and Departments of Pathology (P.A.), University of Wuerzburg, 97080 Wuerzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ritte","sequence":"additional","affiliation":[{"name":"Department of Radiology (C.R.), University of Wuerzburg, 97080 Wuerzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Strasburger","sequence":"additional","affiliation":[{"name":"Department of Clinical Endocrinology (M.Q., C.S.), Charite\u0301 Campus Mitte, Charite\u0301 University Medicine Berlin, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Allolio","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I (S.H., S.W., S.J., B.A., M.F.), University of Wuerzburg, 97080 Wuerzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Fassnacht","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I (S.H., S.W., S.J., B.A., M.F.), University of Wuerzburg, 97080 Wuerzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2019041115532270800_R1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1677\/erc.1.01130","article-title":"Adrenocortical cancer: pathophysiology and clinical management.","volume":"14","author":"Libe","year":"2007","journal-title":"Endocr Relat Cancer"},{"key":"2019041115532270800_R2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1677\/erc.1.01029","article-title":"Management of patients with adrenal cancer: recommendations of an international consensus conference.","volume":"12","author":"Schteingart","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"2019041115532270800_R3","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1210\/jc.2005-2639","article-title":"Adrenocortical carcinoma: clinical update.","volume":"91","author":"Allolio","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041115532270800_R4","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1210\/jc.2005-2730","article-title":"Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients.","volume":"91","author":"Abiven","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041115532270800_R5","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/bjc.1994.183","article-title":"Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients.","volume":"69","author":"Haak","year":"1994","journal-title":"Br J Cancer"},{"key":"2019041115532270800_R6","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00268-001-0047-y","article-title":"Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group.","volume":"25","author":"Icard","year":"2001","journal-title":"World J Surg"},{"key":"2019041115532270800_R7","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/1097-0142(20010901)92:5<1113::AID-CNCR1428>3.0.CO;2-I","article-title":"Adrenocortical carcinoma. Clinical outcome at the end of the 20th century.","volume":"92","author":"Vassilopoulou-Sellin","year":"2001","journal-title":"Cancer"},{"key":"2019041115532270800_R8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1210\/jc.2006-0706","article-title":"Prognostic parameters of metastatic adrenocortical carcinoma.","volume":"92","author":"Assie","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041115532270800_R9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1055\/s-2006-923808","article-title":"Adrenocortical carcinoma: improving patient care by establishing new structures.","volume":"114","author":"Koschker","year":"2006","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2019041115532270800_R10","first-page":"386","article-title":"Mitotane for adrenocortical carcinoma treatment.","volume":"6","author":"Hahner","year":"2005","journal-title":"Curr Opin Investig Drugs"},{"key":"2019041115532270800_R11","first-page":"377","article-title":"CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma.","volume":"67","author":"van Slooten","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"2019041115532270800_R12","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1159::AID-CNCR28>3.0.CO;2-R","article-title":"Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study.","volume":"88","author":"Williamson","year":"2000","journal-title":"Cancer"},{"key":"2019041115532270800_R13","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1677\/erc.1.01025","article-title":"Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial.","volume":"12","author":"Berruti","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"2019041115532270800_R14","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1002\/cncr.10487","article-title":"A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.","volume":"94","author":"Abraham","year":"2002","journal-title":"Cancer"},{"key":"2019041115532270800_R15","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1023\/A:1008377915129","article-title":"Streptozocin and o,p\u2019DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use.","volume":"11","author":"Khan","year":"2000","journal-title":"Ann Oncol"},{"key":"2019041115532270800_R16","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/bjc.1998.530","article-title":"Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Reseau Comete INSERM.","volume":"78","author":"Bonacci","year":"1998","journal-title":"Br J Cancer"},{"key":"2019041115532270800_R17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1200\/JCO.1993.11.1.161","article-title":"Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study.","volume":"11","author":"Bukowski","year":"1993","journal-title":"J Clin Oncol"},{"key":"2019041115532270800_R18","first-page":"1006","article-title":"Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma.","volume":"110","author":"Decker","year":"1991","journal-title":"Surgery"},{"key":"2019041115532270800_R19","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1002\/1097-0142(19910615)67:12<2997::AID-CNCR2820671211>3.0.CO;2-#","article-title":"5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma.","volume":"67","author":"Schlumberger","year":"1991","journal-title":"Cancer"},{"key":"2019041115532270800_R20","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/annonc\/mdf291","article-title":"Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma.","volume":"13","author":"Baudin","year":"2002","journal-title":"Ann Oncol"},{"key":"2019041115532270800_R21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1385\/MO:21:2:167","article-title":"Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenocortical cancer.","volume":"21","author":"Khan","year":"2004","journal-title":"Med Oncol"},{"key":"2019041115532270800_R22","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00268-001-0031-6","article-title":"Cytotoxic treatment of adrenocortical carcinoma.","volume":"25","author":"Ahlman","year":"2001","journal-title":"World J Surg"},{"key":"2019041115532270800_R23","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.1365-2265.2003.01881.x","article-title":"Management of adrenocortical carcinoma.","volume":"60","author":"Allolio","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"Suppl 4","key":"2019041115532270800_R24","first-page":"S3","article-title":"The EGFR family and its ligands in human cancer","volume":"37","author":"Yarden","year":"2001","journal-title":"signalling mechanisms and therapeutic opportunities. Eur J Cancer"},{"key":"2019041115532270800_R25","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/1040-8428(94)00144-I","article-title":"Epidermal growth factor-related peptides and their receptors in human malignancies.","volume":"19","author":"Salomon","year":"1995","journal-title":"Crit Rev Oncol Hematol"},{"key":"2019041115532270800_R26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer.","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"2019041115532270800_R27","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"key":"2019041115532270800_R28","first-page":"1303","article-title":"Biological characteristics of adrenocortical carcinoma: a study of p53, IGF, EGF-r, Ki-67 and PCNA in 17 adrenocortical carcinomas.","volume":"17","author":"Edgren","year":"1997","journal-title":"Anticancer Res"},{"key":"2019041115532270800_R29","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1507\/endocrj.41.471","article-title":"Localization of steroidogenic enzymes in adrenal cortex and its disorders.","volume":"41","author":"Sasano","year":"1994","journal-title":"Endocr J"},{"key":"2019041115532270800_R30","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0046-8177(90)90227-V","article-title":"Immunohistochemical expression of epidermal growth factor receptors in human adrenocortical carcinoma.","volume":"21","author":"Kamio","year":"1990","journal-title":"Hum Pathol"},{"key":"2019041115532270800_R31","first-page":"P145","article-title":"Epidermal growth factor receptor (EGFR) as a potential new target in the treatment of patients with adrenocortical carcinoma: results of pre-clinical studies.","author":"Fassnacht","year":"2007","journal-title":"Ninth European Congress of Endocrinology"},{"key":"2019041115532270800_R32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"2019041115532270800_R33","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/01.cad.0000127664.66472.60","article-title":"Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models.","volume":"15","author":"Higgins","year":"2004","journal-title":"Anticancer Drugs"},{"key":"2019041115532270800_R34","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.2005.05.1474","article-title":"Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.","volume":"25","author":"Gatzemeier","year":"2007","journal-title":"J Clin Oncol"},{"key":"2019041115532270800_R35","first-page":"4838","article-title":"Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.","volume":"57","author":"Moyer","year":"1997","journal-title":"Cancer Res"},{"key":"2019041115532270800_R36","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/cncr.22609","article-title":"Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial.","volume":"109","author":"Dileo","year":"2007","journal-title":"Cancer"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/93\/6\/2057\/9055455\/jcem2057.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T05:40:53Z","timestamp":1555047653000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/93\/6\/2057\/2598205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,1]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2007-2564","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6,1]]}}}